Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 03-Apr-24 5:30 PM View:  | Bashan Dror President and CEO Director | Protalix BioTherapeutics, I... (PLX) | 01-Apr-24 | Grant | 263,960 | -- | -- | 13% 2.02M to 2.28M | |
| 20-Oct-23 6:50 AM View: | Bashan Dror President and CEO Director | Protalix BioTherapeutics, I... (PLX) | 19-Oct-23 | Purchase | 64,516 | $1.40 | $90,483.70 | 95% 68.0K to 132.52K | |
| 17-Aug-23 4:30 PM View: | Naos Yaron Sr. VP, Operations | Protalix BioTherapeutics, I... (PLX) | 15-Aug-23 | Grant | 187,344 | -- | -- | 910% 20.59K to 207.93K | |
| 17-Aug-23 4:30 PM View: | Rubin Eyal Sr. VP and CFO | Protalix BioTherapeutics, I... (PLX) | 15-Aug-23 | Grant | 201,903 | -- | -- | 55% 368.1K to 570.0K | |
| 17-Aug-23 4:30 PM View: | Hayon Yael VP, Research & Development | Protalix BioTherapeutics, I... (PLX) | 15-Aug-23 | Grant | 35,115 | -- | -- | 100% 0 to 35.12K | |
| 17-Aug-23 4:30 PM View: | Bashan Dror President and CEO Director | Protalix BioTherapeutics, I... (PLX) | 15-Aug-23 | Grant | 800,000 | -- | -- | 69% 1.15M to 1.95M | |
| 05-Jan-23 5:08 PM View: | Schwartz Aharon Director | Protalix BioTherapeutics, I... (PLX) | 03-Jan-23 | Purchase | 110,000 | $1.42 | $155,815.00 | 172% 64.0K to 174.0K | |
| 13-Apr-22 4:05 PM View: | Bashan Dror President and CEO Director | Protalix BioTherapeutics, I... (PLX) | 11-Apr-22 | Purchase | 68,000 | $1.50 | $102,000.00 | 6% 1.09M to 1.15M | |
| 28-Feb-22 5:01 PM View: | Bashan Dror President and CEO Director | Protalix BioTherapeutics, I... (PLX) | 25-Feb-22 | Grant | 637,531 | -- | -- | 142% 447.93K to 1.09M | |
| 28-Feb-22 10:00 PM View: | Rubin Eyal Sr. VP and CFO | Protalix BioTherapeutics, I... (PLX) | 25-Feb-22 | Grant | 121,951 | -- | -- | 50% 246.15K to 368.1K | |
| 03-Jun-21 5:40 PM View: | Dexcel Pharma Technologies ... 10% Owner | Protalix BioTherapeutics, I... (PLX) | 03-Jun-21 | Market Sale | 857,506 | $2.25 | $1,932,300.00 | (19%) 4.49M to 3.64M | (10%) |
| 03-Jun-21 5:40 PM View: | Dexcel Pharma Technologies ... 10% Owner | Protalix BioTherapeutics, I... (PLX) | 02-Jun-21 | Market Sale | 61,211 | $2.56 | $156,553.00 | (1%) 4.56M to 4.49M | 3% |
| 13-Aug-20 5:02 PM View: | Bashan Dror President and CEO Director | Protalix BioTherapeutics, I... (PLX) | 11-Aug-20 | Grant | 447,927 | -- | -- | 100% 0 to 447.93K | |
| 13-Aug-20 5:03 PM View: | Rubin Eyal Sr. VP and CFO | Protalix BioTherapeutics, I... (PLX) | 11-Aug-20 | Grant | 246,146 | -- | -- | 100% 0 to 246.15K | |
| 13-Apr-20 4:05 PM View: | Schwartz Aharon Director | Protalix BioTherapeutics, I... (PLX) | 07-Apr-20 | Market Purchase | 64,000 | $2.43 | $155,264.00 | 100% 0 to 64.0K | 42% |
| 16-May-17 9:31 AM View: | Manor Moshe President & CEO Director | Protalix BioTherapeutics, I... (PLX) | 16-May-17 | Market Purchase | 50,000 | $0.81 | $40,500.00 | 100% 0 to 50.0K | (40%) |
| 06-Dec-16 3:26 PM View: | Camber Capital Management LLC 10% Owner | Protalix BioTherapeutics, I... (PLX) | 02-Dec-16 | Market Sale | 2,500,000 | $0.32 | $792,000.00 | (19%) 13.28M to 10.78M | (63%) |
| 16-Sep-16 5:01 PM View: | Shaaltiel Yoseph Executive VP, R&D | Protalix BioTherapeutics, I... (PLX) | 15-Sep-16 | Option Exercise | 122,162 | $0.00 | $122.16 | 18% 673.75K to 795.92K | |
| 15-Dec-15 7:30 AM View: | Yossi Maimon Vice President & CFO | Protalix BioTherapeutics, I... (PLX) | 14-Dec-15 | Market Purchase | 10,000 | $0.78 | $7,800.00 | 5% 185.0K to 195.0K | (34%) |
| 20-Oct-15 2:18 PM View: | Camber Capital Management LLC 10% Owner | Protalix BioTherapeutics, I... (PLX) | 19-Oct-15 | Market Purchase | 4,000,420 | $1.00 | $4,000,440.00 | 18% 22.55M to 26.55M | (48%) |
| 06-Oct-14 6:00 PM View: | Bronfeld Zeev Director | Protalix BioTherapeutics, I... (PLX) | 02-Oct-14 | Acquisition (other) | 324,372 | -- | -- | 10% 3.35M to 3.67M | |
| 06-Oct-14 6:00 PM View: | Bronfeld Zeev Director | Protalix BioTherapeutics, I... (PLX) | 02-Oct-14 | Disposition (other) | 1,509,950 | -- | -- | (41%) 3.67M to 2.16M | |
| 18-Sep-14 6:00 PM View: | Bronfeld Zeev Director | Protalix BioTherapeutics, I... (PLX) | 16-Sep-14 | Disposition (other) Duplicate | 8,556,370 | -- | -- | (72%) 11.9M to 3.35M | |
| 18-Sep-14 5:59 PM View: | Bio-Cell Ltd 10% Owner | Protalix BioTherapeutics, I... (PLX) | 16-Sep-14 | Disposition (other) | 8,556,370 | -- | -- | (85%) 10.07M to 1.51M | |
| 18-Sep-14 6:00 PM View: | Bronfeld Zeev Director | Protalix BioTherapeutics, I... (PLX) | 16-Sep-14 | Acquisition (other) | 1,838,110 | -- | -- | 18% 10.07M to 11.9M | |
| 15-Aug-14 4:30 PM View: | Bio-Cell Ltd 10% Owner | Protalix BioTherapeutics, I... (PLX) | 13-Aug-14 | Market Sale | 4,400,000 | $2.47 | $10,868,000.00 | (30%) 14.47M to 10.07M | 79% |
| 15-Aug-14 4:30 PM View: | Bronfeld Zeev Director 10% Owner | Protalix BioTherapeutics, I... (PLX) | 13-Aug-14 | Market Sale Duplicate | 4,400,000 | $2.47 | $10,868,000.00 | (30%) 14.47M to 10.07M | 79% |
| 16-Aug-13 6:00 PM View: | Akirov Alfred Director | Protalix BioTherapeutics, I... (PLX) | 15-Aug-13 | Market Sale | 2,330 | $5.07 | $11,813.10 | (< 1%) 4.92M to 4.92M | 90% |
| 16-Aug-13 6:00 PM View: | Akirov Alfred Director | Protalix BioTherapeutics, I... (PLX) | 14-Aug-13 | Market Sale | 110,000 | $5.05 | $555,750.00 | (2%) 5.03M to 4.92M | 90% |
| 14-Mar-13 7:00 PM View: | Akirov Alfred Director | Protalix BioTherapeutics, I... (PLX) | 12-Mar-13 | Market Sale | 10,000 | $5.70 | $57,000.00 | (< 1%) 5.04M to 5.03M | 91% |
| 12-Mar-13 6:30 PM View: | Akirov Alfred Director | Protalix BioTherapeutics, I... (PLX) | 11-Mar-13 | Market Sale | 18,300 | $5.72 | $104,737.00 | (< 1%) 5.06M to 5.04M | 91% |
| 12-Mar-13 6:30 PM View: | Akirov Alfred Director | Protalix BioTherapeutics, I... (PLX) | 08-Mar-13 | Market Sale | 16,898 | $5.86 | $99,068.10 | (< 1%) 5.07M to 5.06M | 91% |
| 08-Mar-13 5:04 PM View: | Akirov Alfred Director | Protalix BioTherapeutics, I... (PLX) | 07-Mar-13 | Market Sale | 8,435 | $5.72 | $48,232.60 | (< 1%) 5.08M to 5.07M | 91% |
| 08-Mar-13 5:04 PM View: | Akirov Alfred Director | Protalix BioTherapeutics, I... (PLX) | 06-Mar-13 | Market Sale | 4,700 | $5.69 | $26,737.00 | (< 1%) 5.09M to 5.08M | 91% |
| 18-Jul-12 4:34 PM View: | Almon Einat Brill SVP, Product Development | Protalix BioTherapeutics, I... (PLX) | 16-Jul-12 | Grant Duplicate | 185,000 | -- | -- | 100% 0 to 185.0K | |
| 18-Jul-12 4:37 PM View: | Yossi Maimon Vice President & CFO | Protalix BioTherapeutics, I... (PLX) | 16-Jul-12 | Grant | 185,000 | -- | -- | 100% 0 to 185.0K | |
| 18-Jul-12 4:32 PM View: | Shaaltiel Yoseph Executive VP, R&D Director | Protalix BioTherapeutics, I... (PLX) | 16-Jul-12 | Grant | 210,000 | -- | -- | 45% 463.75K to 673.75K | |
| 18-Jul-12 4:40 PM View: | Lauterbach Sandra Leigh VP, Sales & Commercial Affairs | Protalix BioTherapeutics, I... (PLX) | 16-Jul-12 | Grant | 20,000 | -- | -- | 100% 0 to 20.0K | |
| 18-Jul-12 4:31 PM View: | Aviezer David President & CEO Director | Protalix BioTherapeutics, I... (PLX) | 16-Jul-12 | Grant | 418,000 | -- | -- | 100% 0 to 418.0K | |
| 18-Jul-12 4:38 PM View: | Palash Tzvi Chief Operating Officer | Protalix BioTherapeutics, I... (PLX) | 16-Jul-12 | Grant | 102,000 | -- | -- | 100% 0 to 102.0K | |
| 04-May-12 5:10 PM View: | Almon Einat Brill SVP, Product Development | Protalix BioTherapeutics, I... (PLX) | 02-May-12 | Market Option Sale (Planned) | 166,848 | $7.13 | $1,189,630.00 | (100%) 166.85K to 0 | 93% |
| 04-May-12 5:11 PM View: | Aviezer David President & CEO Director | Protalix BioTherapeutics, I... (PLX) | 02-May-12 | Option Exercise | 450,000 | $0.35 | $159,421.00 | 100% 0 to 450.0K | |
| 04-May-12 5:13 PM View: | Yossi Maimon VP, Chief Financial Officer | Protalix BioTherapeutics, I... (PLX) | 02-May-12 | Market Option Sale (Planned) | 125,964 | $7.13 | $898,123.00 | (100%) 125.96K to 0 | 93% |
| 04-May-12 5:14 PM View: | Shaaltiel Yoseph Executive VP, R&D Director | Protalix BioTherapeutics, I... (PLX) | 02-May-12 | Market Sale (Planned) | 300,000 | $7.13 | $2,139,000.00 | (39%) 763.75K to 463.75K | 93% |
| 04-May-12 5:11 PM View: | Aviezer David President & CEO Director | Protalix BioTherapeutics, I... (PLX) | 02-May-12 | Market Option Sale (Planned) | 450,000 | $7.13 | $3,208,500.00 | (100%) 450.0K to 0 | 93% |
| 04-May-12 5:10 PM View: | Almon Einat Brill SVP, Product Development | Protalix BioTherapeutics, I... (PLX) | 02-May-12 | Option Exercise | 166,848 | $1.47 | $246,076.00 | 100% 0 to 166.85K | |
| 04-May-12 5:13 PM View: | Yossi Maimon VP, Chief Financial Officer | Protalix BioTherapeutics, I... (PLX) | 02-May-12 | Option Exercise | 125,964 | $1.64 | $206,337.00 | 100% 0 to 125.96K | |
| 08-Oct-10 4:10 PM View: | Yossi Maimon VP, Chief Financial Officer | Protalix BioTherapeutics, I... (PLX) | 07-Oct-10 | Payment of Exercise | 7,769 | $9.73 | $75,592.40 | (10%) 77.77K to 70.0K | 95% |
| 08-Oct-10 4:10 PM View: | Yossi Maimon VP, Chief Financial Officer | Protalix BioTherapeutics, I... (PLX) | 07-Oct-10 | Option Exercise | 77,769 | $0.97 | $75,591.50 | 100% 0 to 77.77K | |
| 08-Oct-10 4:10 PM View: | Yossi Maimon VP, Chief Financial Officer | Protalix BioTherapeutics, I... (PLX) | 07-Oct-10 | Market Option Sale (Planned) | 70,000 | $9.67 | $676,900.00 | (100%) 70.0K to 0 | 95% |
